

United States of America FEDERAL TRADE COMMISSION Washington, D.C. 20580

December 4, 2021

CEASE AND DESIST DEMAND

VIA EMAIL TO<u>info@navage.co</u>mand<u>support@navage.co</u>m Mr. Martin R. Hoke, President and Founder RhinoSystems, Inc. 1 American Road, Suite 1100 Brooklyn, Ohio 44144

Re: Unsubstantiated claims for Coronavirus prevention and treatment

Dear Mr. Hoke

This is to advise you that FTC staff has reviewed your website https://www.navage.co/im December 2021. We also reviewed your social media websites https://www.facebook.com/Navage4Lifem/d https://www.youtube.com/user/NavageRocks where you direct consumers to your websiteps://navage.com/to purchase Naväge nasal irrigation products. We have determined that you are unlawfullyeardsing thatNaväge productstreat or prevent Coronavirus Disease 2019 (COVII).

Some examples of Coronavirus prevention or treatmelatims include:

x In an email sent to consumers on September 17, 2021 with the subjectimeçal Trial Preprint: Covid and Twice Daily NASAL IRRIGATION," you state

"SUMMARY: A clinical study using nasal irrigation wascentlypublished on MedRXiv.com[link to https://www.medrxiv.org/, a non peer-reviewed site for new medical research that is overseen by Yale University and the Britishal of Medicine. The primary result is that individuals who tested positive for Covid and immediately began using nasal irrigation twizeday were 8.4 times less likely to be hospitalized or die than thosehowdid not...

Mr. Martin Hoke RhinoSystems, Inc. December 4, 2021 Page2

Please note that a preprint has yet to be evaluated by the scientific community through the peer review processand it may undergo future alterations.

In July, 2020, RhinoSystems, the maker of Naväge, was asked to support a clinical trial designed to test the theory that people who get Covid will have better outcomes if they immediately begin using nasal irrigatiowice a-day, compared to those who don't. The primary measured outcomes were hospital admissions and death. Thearesinly and they are so very encouraging.

In short, Covidpositive individuals who immediately began using nasal irrigatione aday were

е

Mr. Martin Hoke RhinoSystems, Inc. December 4, 2021 Page3

national datase link to https://www.medrxiv.org/content/10.1101/2021.08.16.212620 44v2

PRIMARY RESULT: Clinical trial participants were 8.4 times less likely be hospitalized or die than negrarticipants.

The significant, <u>8old</u> reduction in hospitalization rates by participants who used nasal irrigation is an exceptionally positive result. To put this in context, considentheiral drug by Regenero[link to https://www.fda.gov/newsvents/press announcements/coronavirosvid-19-updatefda-authorizesmonoclonalantibodies treatmentcovid-19] received FDA Emergency Use Approval last November for only a 3-fold reduction in hospitalization rates

I'm sharing this good news with you in the hatpet if you do not already, you will give serious consideration to becomin twice-a-day Naväge user yourself. I can think of very few things you could do for yourself or those you love that are as simple and healthy.

On a more personal appdirely anecdotal note, namely the experience of two, tavidaey Naväge users: Throughout the pandemic, RhinoSystems has been up, running, and manufacturing Naväge Nose Cleaners and SaltPods, and during that time neither my wife, Maria, nor I have missed a day of work due to illnessanks be to God and knock on wood!

Best regards,
Martin ...
Martin R. Hoke
President and Founder..."

- x In an emailsentto consumers on September 20, 2002th the subject line Just in case you missed it: Twice A-Day NASAL IRRI GATION, a Covid Clinical Trial Preprint," you repeated all of the claim described above.
- x In a July 21, 2021 video titled "Naväge 2021 Commerc**a**b-Many Good Things," available at https://www.youtube.com/watch?v=G5zmTLuT,Q8astate:

"The pandemic'N8 108 5y6Themip4 paiNa 2021

Mr. Martin Hoke RhinoSystems, Inc. December 4D2021 Dc -0.001 3..001 b I